Understanding the mechanisms underlying dysregulation of iron balance in CKD patients is holding the promise for development of new therapeutic strategies to improve anemia management, involving hepcidin and hepcidin–ferroportin axis as well as prolyl hydroxylase inhibitors and modulators of hepcidin activity. The gene discussed is HAMP; the disease is chronic kidney disease.